Investors with an interest in Medical - Dental Supplies stocks have likely encountered both Align Technology (ALGN) and Straumann Holding AG (SAUHY). But which of these two stocks presents investors with the better value opportunity right now?
The average of price targets set by Wall Street analysts indicates a potential upside of 31.4% in Align Technology (ALGN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Align Technology reports first-quarter 2025 financial results, reflecting strength in the Imaging Systems & CAD/CAM Services business segment.
The headline numbers for Align Technology (ALGN) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Align Technology (ALGN) came out with quarterly earnings of $2.13 per share, beating the Zacks Consensus Estimate of $1.98 per share. This compares to earnings of $2.14 per share a year ago.
Here is a sneak peek into how these three MedTech stocks, ALGN, TNDM and ICLR, may fare in their quarterly results, slated to be released tomorrow.
Align Technology (ALGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Align Technology's first-quarter 2025 results are likely to reflect the strength in its Clear Aligner business.
Investors with an interest in Medical - Dental Supplies stocks have likely encountered both Align Technology (ALGN) and Merit Medical (MMSI). But which of these two companies is the best option for those looking for undervalued stocks?
Align Technology's Invisalign System, featuring mandibular advancement with occlusal blocks, is now commercially available for Class II malocclusion in the growing number of patients.
Align Technology continues to attract investors' confidence thanks to its share gains in the malocclusion market and strategic deals.